Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
